Publication
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerRenal Cell Carcinomacivic_curation1.00
- drugPalbociclibcivic_curation1.00
- geneCCND1civic_curation1.00
- geneCDKN2Acivic_curation1.00
- geneCDKN2Bcivic_curation1.00
- variantCCND1 Amplificationcivic_curation1.00
- variantCDKN2A Losscivic_curation1.00
- variantCDKN2B Losscivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23898052
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCND1 Amplification1 | ||||||||
| Palbociclib | Renal Cell CarcinomaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 2 | accepted | EID156028 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cycl… (full text at CIViC) PMID 23898052 · Logan et al., 2013 · Open in CIViC | civic |
| CDKN2A Loss1 | ||||||||
| Palbociclib | Renal Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1373Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC) PMID 23898052 · Logan et al., 2013 · Open in CIViC | civic |
| CDKN2B Loss1 | ||||||||
| Palbociclib | Renal Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1374Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC) PMID 23898052 · Logan et al., 2013 · Open in CIViC | civic |
| CDK4 EXPRESSION1 | ||||||||
| Palbociclib | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | B | Supports Sensitivity Response | 3 | rejected | EID345Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer. PMID 23898052 · Logan et al., 2013 · Open in CIViC | civic |